Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
67,928.61 +567.86 (+0.84%) CMC Crypto 200
1,374.47 +43.86 (+3.30%)
Amneal Pharmaceuticals, Inc. (AMRX)
After hours:
| Previous close | 7.38 |
| Open | 7.48 |
| Bid | 7.42 x 300 |
| Ask | 7.45 x 300 |
| Day's range | 7.39 - 7.54 |
| 52-week range | 3.09 - 7.74 |
| Volume | |
| Avg. volume | 1,453,122 |
| Market cap | 2.296B |
| Beta (5Y monthly) | 1.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.73 |
| Earnings date | 09 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.00 |
Business WireAmneal to Report Second Quarter 2024 Results on August 9, 2024
BRIDGEWATER, N.J., July 11, 2024--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time.
Business WireAmneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
BRIDGEWATER, N.J., July 09, 2024--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) ("Amneal" or the "Company") today announced the launch of FOCINVEZ™, a ready-to-use injectable. Unlike other versions of fosaprepitant, this single-dose vial product is free of Polysorbate 80 and does not require reconstitution or dilution and can be administered directly from the vial using the included vial hanger.
- Business Wire
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
PISCATAWAY, N.J., July 01, 2024--Kashiv BioSciences, LLC ("Kashiv" or the "Company") today announced that it has entered into an exclusive licensing agreement for ADL018, a proposed biosimilar to omalizumab referencing XOLAIR®, with Amneal Pharmaceuticals, Inc. ("Amneal") for the United States.
